Propecia is the medication approved by the FDA for the treatment of male pattern hair loss in men (particularly androgenetic alopecia). If you suffer from male pattern hair loss of baldness, consult your doctor and ask him/her if you can take Propecia.
Propecia contains Finasteride, the substance known for its potential to reduce dihydrotestosterone (DHT), a key cause of hair loss. Propecia has been clinically tested and appears to be one of the most effective treatments for hair loss in men. The successful results of Propecia treatment are observed in 9 out of 10 men. A clinical study lasting for 5 years demonstrated high effectiveness and safety of Propecia.
According to the study results, 9 of 10 men in Propecia group had visible hair growth. Their hair loss stopped and hair began grow again. The hair regrowht was observed in more than 48% of men. The stop in hair loss was noted in 42% of men. The independent dermatologists who evaluated the results of the treatment confirmed the benefits of Propecia. The results of men in Propecia group were compared with the results of men from placebo group. 2 of 3 men who took Propecia had increased hair growth measured by hair count. All of the men from placebo group lost hair. Dermatologists involved in the study rated 77% of men from Propecia as having significant improvements.
Propecia is successfully used by many dermatologists in the world to treat male pattern baldness in men. The medication has certain side effects, one of them is a sexual side effect, still, any side effects disappear completely after the treatment is stopped.
I have stated to notice bald spots on my head when I was 24. I tried
Rogaine but it was not of any help. Then I tried with Propecia, and after six
months I have noticed first results. After having used it for seven years, I can
boast with the same hair volume as before. I would you recommend this drug. But
you should be aware you may have a slower sex interest. And the price is not so
In clinical researches for PROPECIA, a few number of men met some sexual side effects, such as lowering of sexual desire, problems in gaining an erection, or a reduction of semen amount. Every of these side effects took place in less than 2% of male patients and they disappeared when the patients quitted treating with PROPECIA.
Usually the patients reported the following symptoms: breast tenderness or enlargement, you should immediately talk with your doctor if you have any changes in your breasts such as pains, knots or nipple discharge. Another symptoms were depression and low sexual desire; some allergic reactions such as eruption, itching, hives, and dropsy of the lips and face; problems with ejaculation that may go on after stopping treatment with PROPECIA; testicular pain; problems in gaining an erection that continued after the treatment; male infertility and/or poor quality of semen; and, in rare cases, male breast cancer. You are recommended to speak with your doctor if you have notices any side effect that troubles you or that does not disappear.
PROPECIA can influence Prostate-Specific Antigen blood test (PSA test) and namely decreases its level. The test is used for the screening of prostate cancer. If you are recommended to make a PSA test, you should tell to the person responsible for this test that you are taking PROPECIA. The responsible health care provider will judge any changes in PSA levels. If there are increases in PSA levels from their low possible level it may be a signal of the presence of prostate cancer. Such changes should be taken into consideration even if the values are still within the normal limits for patients not curing by PROPECIA. And on the contrary you should also tell if you have not been taking PROPECIA because this may influence the results of PSA test. To receive more details talk to your doctor. A risk of a more serious form of prostate cancer is increased if the patient takes at 5 times the dose of PROPECIA.
My son was diagnosed with hair loss. He takes Propecia since he started losing his hair at nineteen. This drug working pretty well so far. I want to believe his hair has stopped thinning.
He have had great results with Propecia. The only down side to the drug is that Propecia is very expensive and most insurance will not cover it. But I recommend to you buy it online, in Internet you can find a good price for you!
Very important know that a child or a woman mustn’t take Propecia.
If a woman is exposed to it during pregnancy, Propecia can cause birth defects . Risk of developing prostate cancer may increase, when you use Propecia. Visit a doctor and perform tests to make sure you do not have other problems .
More information about hair loss you may find in other website.
If you want to take Propecia you should visit to a doctor and consult with him. tell him about the next condition:
- prostate cancer;
- abnormal liver enzyme liver disease or tests ;
- a bladder muscle disorder;
- if you have ever had an allergy to Avodart;
- if you are unable to urinate; or
- stricture of your urethra.
During clinical studies of Propecia no meaningful interactions with other medications have been detected. No specific interaction studies were done. Still Finasteride medication was studied in combination with other medications including acetaminophen, acetylsalicylic acid, α-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, NSAIDs, and quinolone anti-infectives. No evidence of clinically meaningful interactions of Finasteride with the mentioned medications was noticed.
Finasteride does not have any influence on the cytochrome P450-linked drug-metabolizing enzyme system. The drugs that have been tested in man who used Finasteride include antipyrine, digoxin, propranolol, theophylline, and warfarin. No clinically significant drug interactions were observed.
The effectiveness of Propecia was assessed in 1879 men with mild to moderate male pattern hair baldness. Men involved in the studies were between 18-41 years of age.
3 main double-blind, randomized, placebo-controlled studies were held during a year of treatment. The main purposes of these studies were to assess the hair growth and make ratings of photos helpful in evaluation of the results.
The additional goal of the studies was to assess the possibility of sexual side effects occurrence in patients taking finasteride.
Two main studies involved 1553 men with mild to moderate vertex hair loss. The third study enrolled 326 men with mild to moderate baldness in the anterior mid-scalp area (without or with vertex baldness).
Of these men about 1200 with baldness at the top of the head took part in extra prolonged studies (5 year-study).
Upon the whole men taking Propecia had significant increases in the number and quality of scalp hair in the first 12 months of the treatment. The improvement was kept during the long-term treatment. Men taking placebo had persistent hair loss.
Known ability of Finasteride to be metabolized in the liver mainly per the cytochrome P4503A4 enzyme should be taken in consideration when the medication is administered to the patients with moderate to severe liver impairment. The research on Finasteride metabolic characteristics has shown that the drug has two metabolites, the t-butyl side chain monohydroxylated and monocarboxylic acid metabolites.
The average terminal half-life of the drug in plasma is 5-6 hours in healthy men in the age from 18-60 years of old. Finasteride is mainly excreted in the feces (about 51-64%) and to a lesser degree in the urine (ranging from 32 to 46% of the oral dose).
The medication is usually well-tolerated, still some precautions should be made in certain groups of patients including geriatrics (men older than 65 years of age) and men with severe renal and liver impairment. Elder men have decreased rate of Finasteride elimination from the body. Special dose adjustments are necessary in patients with kidney or liver diseases.
Finasteride clinical studies demonstrate that the average bioavailability of the medication in the dose of 1 mg in healthy volunteers ranges from 26 to 170% (65%). Finasteride max plasma level is reached 1-2 hours after the oral dose. The bioavailability of the medication is not influenced by food intake.
The average steady-state volume of distribution (Vd) is 76 liters. About 90% of finasteride circulating is bound to plasma proteins. Multiple doses of finasteride provide a slow cumulation stage. The medicine can cross the blood-brain barrier.
The other characteristic of finasteride is the measurement of semen levels in men taking 1 mg of medicine per day during 6 weeks. In 60% of test participants finasteride levels in the semen were not found. The average finasteride level in the semen was 0.26 ng/mL, the highest point detected was 1.52 ng/mL. It shows that the exposure to finasteride through the semen (during vaginal intercourse) is insignificant and has not effect on the developmental abnormalities in the fetus.
Being a specific inhibitor of type II 5α – reductase, which represents an intracellular enzyme modifying the androgen testosterone into DHT, Finasteride is proven to be a selective in the type II isozyme. The type II isozyme is located in prostate, seminal vesicles, epididymides, liver and hair follicles.
Propecia mechanism of action is the inhibition of the type II isozyme. The inhibition is accompanied by the decline of the inhibitor to dihydrofinasteride and adduct substance with NADP+.
Finasteride shows no relatedness for the androgen receptor and any androgenic, antiandrogenic, estrogenic, antiesterogenic, or progestational effects.
The restriction of type II 5α – reductase does not allow the peripheral transformation of testosterone to DHT, this results in meaningful reduction in serum and tissue DHT concentrations. The reduction of DHT to 65% is reached within 24 hours after oral dose – 1 mg tablet.
The levels of testosterone and estradiol got increased up to 15%, still they remain within the normal ranges.
In MPHL or androgenetic alopecia the balding scalp has tiny hair follicles and enlarged levels of DHT in comparison with healthy hairy scalp. Finasteride helps to reduce the DHT levels in the scap area and stops the main factor in the development of androgenetic alopecia in patients genetically predisposed to this condition.
The clinical study of finasteride in patients with MPHL showed increases in hair counts and an improvement in the proportion of anagen hairs in more than 68% of test participants.